Estimation of Quality-adjusted Life Years alongside clinical trials: the impact of 'time-effects' on trial results.

about

Estimation of Quality-adjusted Life Years alongside clinical trials: the impact of 'time-effects' on trial results.

Item

http://www.wikidata.org/entity/Q55270260

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Estimation of Quality-adjusted ...... ime-effects' on trial results.

@en

Estimation of Quality-adjusted ...... ime-effects' on trial results.

@nl

type

Item

label

Estimation of Quality-adjusted ...... ime-effects' on trial results.

@en

Estimation of Quality-adjusted ...... ime-effects' on trial results.

@nl

prefLabel

Estimation of Quality-adjusted ...... ime-effects' on trial results.

@en

Estimation of Quality-adjusted ...... ime-effects' on trial results.

@nl

P1476

Estimation of Quality-adjusted ...... time-effects' on trial results

@en

P2093

Morro M L Touray

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT)

Analysis of cost data in randomized trials: an application of the non-parametric bootstrap.

Bootstrapping: estimating confidence intervals for cost-effectiveness ratios.

Strategy for intention to treat analysis in randomised trials with missing outcome data.

Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting.

Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).

Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review.

Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial

The NICE cost-effectiveness threshold: what it is and what that means.

Infliximab in ulcerative colitis.

P304

109-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JPHS.12218

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Morro M.L. Touray

P577

2018-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29861785

http://www.w3.org/2001/XMLSchema#string

P932

5969066

http://www.w3.org/2001/XMLSchema#string